[HTML][HTML] Evolving treatment paradigms for PCV

BJ Fenner, CMG Cheung, SS Sim, WK Lee… - Eye, 2022 - nature.com
Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular AMD (nAMD) that
accounts for a significant proportion of nAMD cases worldwide, and particularly in Asia …

Multimodal imaging comparison of polypoidal choroidal vasculopathy between Asian and Caucasian populations

F Corvi, S Chandra, A Invernizzi, L Pace, F Viola… - American journal of …, 2022 - Elsevier
Purpose Differences in multimodal imaging features between Asian and Caucasian eyes
may contribute to our understanding of the etiology of the polypoidal choroidal vasculopathy …

[HTML][HTML] Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes

N Tanaka, K Azuma, S Aoki, K Kitamoto, K Ueda… - Graefe's Archive for …, 2024 - Springer
Purpose To examine the long-term visual outcomes after initial treatment with combined
photodynamic therapy (PDT) or aflibercept treat-and-extend (TAE) monotherapy in patients …

Polypoidal choroidal vasculopathy features vary according to subfoveal choroidal thickness

JM Jordan-Yu, KYC Teo, U Chakravarthy, A Gan… - Retina, 2021 - journals.lww.com
Purpose: To evaluate associations between choroidal thickness and features of polypoidal
choroidal vasculopathy (PCV) lesions based on multimodal imaging. Methods: This cross …

[HTML][HTML] Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal …

IH Ma, Y Hsia, YT Hsieh, TC Ho, TT Lai, CM Yang… - Scientific Reports, 2021 - nature.com
To provide real-world experiences of treating polypoidal choroidal vasculopathy (PCV)
patients with photodynamic therapy (PDT) plus intravitreal injection of ranibizumab or …

Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy

Y Nomura, S Aoki, K Kitamoto, K Ueda… - Graefe's Archive for …, 2024 - Springer
Background Long-term results of photodynamic therapy (PDT) combined with vascular
endothelial growth factor (VEGF) inhibitors for pachychoroid neovasculopathy (PNV) are not …

Long-term predictors of anti-VEGF treatment response in patients with neovascularization secondary to CSCR: a longitudinal study

GM Cozzupoli, R Sacconi, B Tombolini… - Graefe's Archive for …, 2024 - Springer
Purpose To identify the baseline predictors of anti-VEGF treatment response at 3 years in
patients affected by choroidal neovascularization (CNV) secondary to central serous …

Quantitative analysis of branching neovascular networks in polypoidal choroidal vasculopathy by optical coherence tomography angiography after photodynamic …

WY Wang, CH Yang, TC Chen, YT Hsieh… - Graefe's Archive for …, 2022 - Springer
Purpose To study serial changes in branching neovascular networks (BNN) by using optical
coherence tomography angiography (OCTA) in patients with polypoidal choroidal …

[HTML][HTML] Choroidal Morphology on Ultra-Widefield Indocyanine Green Angiography and Response to Aflibercept in Pachychoroid Neovasculopathy

SY Han, SH Lee, P Lee, H Ra, J Baek - Pharmaceuticals, 2023 - mdpi.com
Purpose: This study assessed the relationship between the choroidal morphology and short-
term response to aflibercept treatment in pachychoroid neovasculopathy (PNV). Methods …

Locational agreement of near-infrared autofluorescence with choroidal vascular hyperpermeability in central serous chorioretinopathy

K Azuma, Y Nomura, K Kitamoto, Y Hashimoto… - Retina, 2022 - journals.lww.com
Purpose: To characterize the findings of eyes with choroidal vascular hyperpermeability
(CVH), a hallmark of central serous chorioretinopathy, using multimodal imaging and …